BioLife Solutions, Inc.

The next ScaleReady and Emily Whitehead Foundation G-Rex Grant Tour Stop is in ONE week on August 20!

Don’t miss this event if you’re in the Los Angeles area. 🌇 🌊⭐

Stop by the BioLife table to meet and chat with Amy Ma and Rebecca Mercier about improving your cryopreservation process, storage containers, closed-systems, thawing optimization, and more.

Highlights:

🌴 Two business roundtables
🌴 Hearing from CAR-T therapy patient-advocate Laurie Adami
🌴 Progress in solid tumor research with CAR-T therapy
🌴 Advancements in ex vivo CGT research

Register soon:

Los Angeles G-Rex Grant Tour | ScaleReady Join the G-Rex Grant Tour in Los Angeles, CA. Sign up to foster local collaboration, shape the future of cell therapy, and catalyze progress.

Are you attending Phacilitate'a Advanced Therapies Europe in Barcelona, September 7-9? 🎨☀️

Come by to see us at Stand 54. Andreas Giger, Jordi Marti Gascon, and Carlos Santalla Formoso of Bexen Bioservices will be onsite.

They are here to discuss and help you work through any issues - from scaling up after R&D, navigating clinical trials, or optimizing biopreservation protocols for commercialization. We’re ready to work together to streamline and strengthen your processes.

Let’s get together over tapas, escalivada, and fideua! 🥘🦐

➡️ Find out more: https://www.phacilitate.com/advanced-therapies-europe

Can an end-to-end autologous CAR-T/TCR workflow deliver consistent performance when starting with cryopreserved leukopaks?

On August 25, in a new webinar with Cell & Gene and CARR Biosystems, Dr. Alireza Abazari and Robert Bilsky will present their latest findings from this study. 💡

🔎 Both will examine how key processing steps and operating parameters affect cell health, cell recovery, viability, consistency, and overall manufacturing reproducibility.

🔎 You will also discover practical approaches for developing reproducible, closed-system workflows that enhance manufacturing reliability, minimize risk, and support efficient scale-up from clinical to commercial production.

Register here: https://event.on24.com/wcc/r/5256157/7AB18447AC92F573A7F7B76F046CB5C7?mode=login

BioLife Solutions Reports Second Quarter 2026 Financial Results

Total revenue of $28.5 million, up 21% over Q2 2025

Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026

*Due to the pending acquisition of BioLife by Repligen, BioLife will not be hosting a conference call.

Read the press release: https://investors.biolifesolutions.com/2026-08-06-BioLife-Solutions-Reports-Second-Quarter-2026-Financial-Results

We hope to see many Seattle locals on Saturday, August 8, for the annual Fred Hutch Obliteride.

Please come out to cheer for the BioLife team and many others as we walk and run in this 5K event to help raise funds for cancer research at Fred Hutch Cancer Center. We’re proud to sponsor this event and participate again this year! 📣 🙌

If you feel inclined, please contribute to our team: https://secure.fredhutch.org/site/TR?team_id=24460&pg=team&fr_id=2251

100% of the proceeds go to advancing cancer research, finding cures quicker, and supporting individual scientists and programs at Fred Hutch. We appreciate the support. 💙 🧡



Image credit: Obliteride website

Would you like to boost your team’s experience with lab techniques applicable to cell and gene therapy manufacturing in a GMP setting?

Sign up for a hands-on, expert-led training session by August 14! ✅

📅 September 14-18, 2026
📍 Georgia Tech
🔬 Hosted by ISCT and Cell Manufacturing Technologies (CMaT)

The BioLife team is excited to support this training event. Vicky Tran will be onsite to discuss the importance of closed-system containers & processing, and automated aseptic fluid management during a Lunch & Learn session on Thursday, September 17.

👉 Register by August 14: https://www.isctglobal.org/workforce-development/hands-on-laboratory-bootcamp-for-cell-therapy-biomanufacturing

Learn more: https://youtu.be/5wsteu4IrdU?si=yYgADEMEhs-_IQ2D

In a new Cell & Gene Therapy Insights interview, Editor Will Rich and Dr. Jason Acker discuss the history and evolution of biopreservation science for the cell and gene therapy field.🧬

❄️ Dr. Acker dives into how cryopreservation processes should evolve from being viewed as simply logistics to being recognized as a critical and strategic manufacturing step that directly determines the quality, cost, and clinical performance of these advanced therapies.

❄️ Rich and Dr. Acker also examine the cryobiology knowledge gap and how to bridge that in the CGT industry, and cutting-edge technologies that could change how these therapies are secured, stored, and distributed at the point of care.

Read on: https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/3892/frozen-in-time-rethinking-cryopreservation-as-a-core-process-parameter-in-cell-and-gene-therapy

BioLife Solutions, Inc. has entered into a definitive merger agreement with Repligen Corporation.

Repligen hosted a conference call and webcast today to discuss the proposed transaction. The webcast will also be available for replay through Repligen’s Investor Relations website.

Read the full announcement and access the webcast details:
https://www.globenewswire.com/news-release/2026/07/22/3331162/0/en/repligen-to-acquire-biolife-solutions-expanding-its-cell-therapy-capabilities-with-market-leading-biopreservation-media.html

When we’ve discussed how to bring down the costs of cell therapy manufacturing with many of you, the conversation usually focuses on automation, facility design, and scaling up.
But what if there were downstream factors being overlooked that could significantly reduce costs? 💸

Dr. Steven Thompson suggests in Cell & Gene Therapy Review that looking earlier in the process at cytokine selection, quality, and container packaging can make a huge difference. ⚗️ 🧪

What should you consider?

💡 Cytokine type and choice affect therapeutic performance, as cytokines determine whether cells remain healthy, durable, and persistent; or if they become exhausted during manufacturing.

💡 Cell quality can matter more than cell quantity.

💡 Closed-system packaging and compatibility may reduce costs by minimizing the need for Grade A environments.

💡 Better control over cytokine inputs and handling could improve reliability and lower the cost per therapy.

Read the full scoop here:

Cell therapy’s real cost problem starts in the culture flask Some of the most actionable levers may sit earlier in the process than the industry has been looking.

Proud to support the Emily Whitehead Foundation and their Believe Bundle program.